UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

The Journal of infectious diseases, 2018-07, Vol.218 (5), p.748-756

2018

Volltextzugriff (PDF)

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Gastroenterology (New York, N.Y. 1943), 2010-03, Vol.138 (3), p.913-921

2010

Volltextzugriff (PDF)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology journal, 2017-05, Vol.14 (1), p.101-101, Article 101

2017

Volltextzugriff (PDF)

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients

Journal of acquired immune deficiency syndromes (1999), 2014-03, Vol.65 (3), p.283-289

2014

Volltextzugriff (PDF)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

BMC gastroenterology, 2017-02, Vol.17 (1), p.26-26, Article 26

2017

Volltextzugriff (PDF)

Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model

PloS one, 2015-05, Vol.10 (5), p.e0126959-e0126959

2015

Volltextzugriff (PDF)

Effect of Oral JNJ-53718678 (JNJ-678) on Disease Severity in Healthy Adult Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus (RSV): A Placebo-Controlled Challenge Study

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects

Clinical pharmacokinetics, 2017-11, Vol.56 (11), p.1331-1342

2017

Volltextzugriff (PDF)

PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials

Antiviral research, 2018-05, Vol.153, p.70-77

2018

Volltextzugriff (PDF)

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

Gastroenterology (New York, N.Y. 1943), 2012-11, Vol.143 (5), p.1176-1178.e6

2012

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment

Drugs in R&D, 2015-09, Vol.15 (3), p.261-270

2015

Volltextzugriff (PDF)

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

Antiviral therapy, 2011-01, Vol.16 (7), p.1021-1033

2011

Volltextzugriff (PDF)

ucb L059, a novel anti-convulsant drug: pharmacological profile in animais

European journal of pharmacology, 1992-11, Vol.222 (2), p.193-203

1992

Volltextzugriff (PDF)

In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model

Methods in molecular biology (Clifton, N.J.), 2013, Vol.1030, p.373

2013

Volltextzugriff (PDF)

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies

Journal of acquired immune deficiency syndromes (1999), 2014-03, Vol.65 (3), p.299-305

2014

Volltextzugriff (PDF)

Discovery and Development of the HCV Protease Inhibitor TMC435

Antiviral Drugs, 2011, p.273-286

2011

Volltextzugriff (PDF)

Superiority of Micrococcus lysodeikticus to BCG in chemo-immunotherapy of advanced L1210 leukaemia

European journal of cancer & clinical oncology, 1981-01, Vol.17 (8), p.849-856

1981

Volltextzugriff (PDF)

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

European journal of pharmacology, 1993-01, Vol.230 (3), p.389-389

1993

Volltextzugriff (PDF)

The obtention of high-titer antibodies of restricted heterogeneity against lysozyme methyl ester in rabbits vaccinated with Micrococcus lysodeikticus

Molecular immunology, 1981-01, Vol.18 (8), p.781-790

1981

Volltextzugriff (PDF)

Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors

European journal of cancer, 1978, Vol.14 (1), p.23-31

1978

Volltextzugriff (PDF)

Antitumour immunoprotection by an immunobacterial lectin approach

European journal of cancer, 1976-11, Vol.12 (11), p.877-888

1976

Volltextzugriff (PDF)

Influence of anti- Micrococcus immunoglobulins on the proliferation of normal immunocompetent cells in inbred mice

Molecular immunology, 1979-11, Vol.16 (11), p.965-974

1979

Volltextzugriff (PDF)

The Immune Response of Mice to Micrococcus lysodeikticus : Evidence for Serum-Mediated Immunoregulation

Biochemical Society transactions, 1977-08, Vol.5 (4), p.1156-1157

1977

Volltextzugriff (PDF)

Biochemical properties that accompany the production of homogeneous antibody response: a general mechanism hypothesis [proceedings]

Biochemical Society transactions, 1977, Vol.5 (4), p.1158-1159

1977

Volltextzugriff (PDF)

Comparison between the effects of Micrococcus Lysodeikticus, bacterial cell wall and related polysaccharides in the non-specific tumour immunotherapy of Ehrlich ascites tumour growth

European journal of cancer, 1979, Vol.15 (1), p.53-61

1979

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)
Buchkapitel
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model

Effect of Oral JNJ-53718678 (JNJ-678) on Disease Severity in Healthy Adult Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus (RSV): A Placebo-Controlled Challenge Study

Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects

PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

ucb L059, a novel anti-convulsant drug: pharmacological profile in animais

In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies

Discovery and Development of the HCV Protease Inhibitor TMC435

Superiority of Micrococcus lysodeikticus to BCG in chemo-immunotherapy of advanced L1210 leukaemia

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

The obtention of high-titer antibodies of restricted heterogeneity against lysozyme methyl ester in rabbits vaccinated with Micrococcus lysodeikticus

Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors

Antitumour immunoprotection by an immunobacterial lectin approach

Influence of anti- Micrococcus immunoglobulins on the proliferation of normal immunocompetent cells in inbred mice

The Immune Response of Mice to Micrococcus lysodeikticus : Evidence for Serum-Mediated Immunoregulation

Biochemical properties that accompany the production of homogeneous antibody response: a general mechanism hypothesis [proceedings]

Comparison between the effects of Micrococcus Lysodeikticus, bacterial cell wall and related polysaccharides in the non-specific tumour immunotherapy of Ehrlich ascites tumour growth

Suchergebnisse filtern